Scholar Rock (SRRK) Jefferies Global Healthcare Conference summary
Event summary combining transcript, slides, and related documents.
Jefferies Global Healthcare Conference summary
17 Nov, 2026U.S. approval and launch
FDA approved ISEMBYLD on Sept. 11, 2026, as the first muscle-targeted SMA therapy; U.S. launch is underway for patients age 2+ receiving ongoing SMN2-targeted treatment.
Global reach ambition covers 35,000–40,000 patients receiving an SMN-targeted therapy, across up to 50 countries.
In the first six weeks through October, treatment-naive enrollment forms exceeded forms for patients transitioning from early access or long-term extension programs.
More than one-third of the top 140 U.S. SMA treatment centers submitted enrollment forms; demand was geographically broad and steady week to week.
Enrollees included children and a substantial number of adults, varied background SMN therapies, and improving, plateaued, or declining motor-function trajectories.
Access and commercial outlook
Anthem and Centene published medical policies aligned with the FDA label; the two payers cover 47 million commercial lives.
Intent-to-treat to first infusion averages 60–90 days at launch; a drug-specific J-code is expected April 1, 2027, after the required two-quarter wait following September filing.
Conversion time is expected to move toward 2–3 weeks over the year after approval as J-code, formularies, and medical policies are established; expected conversion rate is 85% or more.
Most enrolled patients were expected to receive first infusion in early 2027; disclosures will track center reach, demand, conversion, payer coverage, and revenue.
Estimated net annual price is ~$310,000; WAC is $11,659 per vial, with a gross price near $450,000 based on ~3 vials per infusion and 13 annual infusions. Medicaid, 340B discounts, and infusion frequency affect net price.
Ex-U.S. expansion
EMA validated the resubmitted MAA; CHMP opinion is expected in H1 2027, with a Germany launch expected later in 2027, followed by country-level pricing and reimbursement agreements.
Japan’s JNDA was filed two months ahead of guidance and accepted for priority review; PMDA typically targets a nine-month review, with launch opportunity next year.
The targeted global population is already receiving SMN-targeted therapy in countries with rare-disease reimbursement; those therapies represent a $5B+ annual market, with 64% of revenues outside the U.S.
Latest events from Scholar Rock
- ISEMBYLD gains broad early uptake as global launches advance into 2027.SRRK
UBS Global Biopharma Conference 2026 - ISEMBYLD launched with $0.57M in Q3 revenue as access and global expansion advance.SRRK
Q3 2026 - FDA approves ISEMBYLD, the first muscle-targeted SMA therapy, with immediate U.S. launch.SRRK
FDA announcement - Apitegromab set for 2026 launch as first muscle-targeted SMA therapy, driving global expansion.SRRK
Corporate presentation - Apitegromab nears FDA approval as a first-in-class SMA therapy, with global launch plans underway.SRRK
Citigroup’s Biopharma Back to School Summit 2026 - FDA decision on apitegromab for SMA expected by September 30, with global launches planned.SRRK
12th Annual Cantor Fitzgerald Global Healthcare Conference - Apitegromab nears FDA approval with dual manufacturing paths and strong launch readiness.SRRK
Canaccord Genuity's 46th Annual Growth Conference - FDA decision on apitegromab expected by September 30, 2026, with strong cash reserves and launch readiness.SRRK
Q2 2026 - Apitegromab plus tirzepatide preserved lean mass and improved weight loss quality in obesity.SRRK
Study Update